Recursion Pharmaceuticals (RXRX) Goodwill (2020 - 2026)

Recursion Pharmaceuticals' Goodwill history runs 7 years deep, the most recent figure standing at $160.2 million for Q1 2026.

• Quarterly Goodwill rose 1.3% year-over-year to $160.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160.2 million (up 1.3% YoY) and the FY2025 annual result came in at $162.2 million, up 8.92% from the prior year.
• Goodwill was $160.2 million for Q1 2026 at Recursion Pharmaceuticals, down from $162.2 million in the prior quarter.
• Across five years, Goodwill topped out at $164.3 million in Q2 2025 and bottomed at $801000.0 in Q2 2022.
• A 5-year average of $84.6 million and a median of $52.1 million in 2023 frame the typical range for Goodwill.
• Annual changes were most pronounced in 2022 — Goodwill changed 0.0% — and 2023, when it surged 6398.88%.
• Recursion Pharmaceuticals' Goodwill stood at $801000.0 in 2022, then jumped by 6398.88% to $52.1 million in 2023, then surged by 185.99% to $148.9 million in 2024, then increased by 8.92% to $162.2 million in 2025, then retreated by 1.23% to $160.2 million in 2026.
• Business Quant data shows RXRX's Goodwill at $160.2 million in Q1 2026, $162.2 million in Q4 2025, and $162.0 million in Q3 2025.